The membranes of *L*-PRF (fibrin rich in platelets and leukocytes) and its derivatives (A-PRF, *i*-PRF):

Use as a source of stem cells in regenerative wound therapy in horses.

Alessandro Crisci*[1,2,3], Antonella Conte [4]

[1] School of Medicine, University of Salerno Italy, 84084 Fisciano SA, Italy;

[2] Unit of Dermosurgery Cutaneous Transplantations and Hard-to-HealWound,"Villa Fiorita"Private Hospital, 81031 Aversa CE, Italy;

[3] Institute for the Studies and Care of Diabetics, Abetaia, 81020 Casagiove CE, Italy;

[4] Veterinarian Freelancer, Caserta, Italy;

*Corresponding author: Prof. Alessandro Crisci, Department of Medicine, Surgery and Dentistry "Salernitan Medical School", University of Salerno, Fisciano (SA), Italy; E-mail: alcrisci@unisa.it telefono:3388722799

***Abstract*—Developing a multidisciplinary field of tissue engineering aims to recover, improve or supplant typically damaged or missing tissues for a collection of conditions brought about by trauma, malady and old age. To guarantee that tissue engineering techniques are generally relevant in the clinical setting, it is important to adjust them so that they are promptly accessible and moderately simple to use in the everyday clinical schedule. Consequently, the steps between preparation and application must be limited and improved to make them practical in application. The general objective of creating platelet concentrates of natural origin can be delivered near the patient to quicken the implantation procedure, being monetarily practical for the patient and the health framework. Fibrin rich in platelets and leukocytes (PRF) and its derivatives (L-PRF, A-PRF, i-PRF) has been utilized in a wide collection of medical fields for delicate tissue restoration. Practically all platelets (>97%) are missing within test-tubes in groups tested after PRF membrane extraction. Growth Factors liberated by platelets contained in derivatives of L-PRF induce and control the proliferation and migration of other cell types, associated with tissue repair, similar to smooth cell muscles (SMCs) and mesenchymal stem cells (MSCs). Conclusively, the outcomes of this work feature the positive effects of PRF on wound healing after regenerative treatment for the administration of different delicate tissue defects found in wound care.**

Keywords: *blood derivatives; growth factors; leucocyte, platelet-rich fibrin; injectable platelet-rich fibrin; L-PRF wound box; stem cells;*

I. INTRODUCTION

The latest scientific proof proposes that platelets could assume a new role in tissue repair and in vascular remodeling, other than being dynamic actors in inflammatory and immune reactions. Platelets discharge naturally dynamic proteins and different contents, ready to impact a progression of procedures, favoring cell intake, growth and morphogenesis. These contents are discharged or uncoated on the surface of induced platelets. The platelet ability to discharge contents within a clot makes the clot itself a natural autologous basis of growth variables and cytokines, which can be remedially used to quicken and accelerate physioscientific healing forms. A considerable lot of these contents are assembled and stored in platelets α-granules, effectively related to Scanning Electron Microscope (SEM) and with immunofluorescence staining [1].

The fine fibrin fibers contained in HPC (Human Platelet Concentrate) could be identified with the high initial concentration of platelets in HPC (3-5x10^{11} platelets/l), where local procoagulant action could even be improved through the beginning of pro-thrombotic stimuli enhancement, and it prompts a practically dangerous thrombin generation, therefore causing an expansion in fibrinogenesis on the surface of platelets, which thus prompts fibrin growth and polymerization [1].

The presentation of blood concentrates, for example, Platelet-Rich Plasma and Fibrin (PRP/PRF) was the initial move toward meeting clinical necessities [2] (Figure 1). This blood concentrate is gotten is obtained from the patient's fringe blood after one-step centrifugation without anticoagulants to produce a platelet- and leucocyte-rich framework. The presence of platelets, leucocytes, and fibrin was recently demonstrated to be basic for wound healing [3,4]. Furthermore the capability of leucocytes to impact

angiogenesis and lymphomagenesis, this fibrin network, containing leucocytes and platelets, is the basis of cytokines and growth factors, which are primary membranes during the process of injury healing [5]. The utilization of explicit plastic tubes favors non-clotting PRF and brought about the improvement of a fluid PRF-based network (fluid PRF) created without the requirement for anticoagulants. Beforehand, a precise study explored the impact of the applied relative centrifugal force (RCF) on the synthesis and bioactivity of PRF-matrices.

This fibrin platform, which has no cytotoxic potential, is acquired from 9 ml of the patient's blood after 1 phase of centrifugation and contains a collection of blood cells – including platelets, B and T lymphocytes, monocytes, stem cells, and neutrophil granulocytes – Furthermore growth factors.

Moreover, L-PRF (likewise called leukocyte-PRF) contains white blood cells, necessary cells that are significant during the injury healing process [6]. In addition, since white blood cells, including neutrophils and macrophages, are among the first kinds of cells present in wound sites, their role additionally incorporates phagocytic fragments, microbes, and necrotic tissue, accordingly avoiding infection. Macrophages are likewise key cells derived from the myeloid genealogy and are viewed as one of the key cells associated with growth factor secretion during wound healing, including the transforming growth factor-beta (TGF-β), PDGF and growth factor vascular endothelium (VEGF) (Figure 2). These cells, together with neutrophils and platelets, are key membranes in wound healing and in mix with their growth factors/discharged cytokines can encourage tissue restoration, the solution of fresh blood vessels (angiogenesis) and the infection prevention.



Fig.1. *Different types of human platelet concentrates (HPCs): PRP (Platelet-rich plasma); PRF (Platelet-rich fibrin); P-PRP (Pure Platelet-rich plasma); L-PRP (Leukocyte and Platelet-rich plasma); P-PRF (Pure Platelet-rich fibrin); L-PRF (Leukocyte and Platelet-rich fibrin); i-PRF (Injectable Platelet-rich fibrin); A-PRF (Advanced Platelet-rich fibrin);*

L-PRF: In the longitudinal area of the L-PRF coagulum, created in accordance with the standard centrifugation protocol (30" of speeding up, 12' at 2700 rpm [816 g-force] and 36" of deceleration and stopping)[6], a thick fibrin clot is available with negligible inter-fiber space. Cells are observed all through the blood clot, albeit diminishing towards the most distal fragments of the PRF clot (Figg.1 and 3).

Advanced-PRF: The PRF clots framed with the A-PRF centrifugation protocol (Advanced-PRF) (1300 rpm, 8 minutes)(189 g-force)[7] indicated a more liberated structure with more inter-fiber space and more cells can be included in the fibrin-rich clot. Moreover, the cells are more uniformly dispersed in the clot than L-PRF, and a few cells can likewise be found in the most distal fragments of the clot. A representative picture for cellular circulation within A-PRF is presented in Figure 4.



Fig. 2. *Function of platelets in skin wounds.*



Fig.3. *Above: L-PRF membrane 0 min after compression (haematoxylin-eosin staining). Under Membrane A-PRF 0 min after compression (haematoxylin-eosin staining). The PRF layers were fixed in a 10% neutral formalin buffer solution at pH 7.2 for 48 hours and incorporated in paraffin according to the standard procedure. Twenty serial sections (7 µm thickness) of each sample were cut using a microtome. Above: (A) proximal III 40 × fibrin on the right, central lymphocytes, erythrocytes and neutrophils granulocytes on the left; (B) mean III 25 × fibrin pattern; (C) III distal 60 × fibrin pattern (Crisci A. et al. 2017).*
Below: Head (A), Body (B), Tail (C) of self-compressed membrane of Horse A-PRF (ingr. 40x hematoxylin-eosin). Abundant Leukocytes (neutrophils) are highlighted together with erythrocytes distributed in the fibrin lattice in A and B. In C presence of abundant lattice and scarce cells.

PRF injectable formulation: The growth of an injectable formulation of PRF (referred to as i-PRF) [8,9] (centrifuged at 700 rpm [60 g-force] for 3 minutes) was sought after with the objective of conveying a platelet concentrate that is simple to use by specialists in fluid formulation that can be utilized alone or effectively combined with different biomaterials.

Exploiting increasingly slow centrifugation speeds, a more prominent presence of regenerative cells with higher concentrations of growth variables can be observed contrasted with other PRF formulations utilizing higher centrifugation rates. Ghanaati et al.[7] reported that speed and time do not influence monocyte and stem cell concentrations, yet impact platelet and neutrophil concentrations. Subsequently, A-PRF contains more platelets; mostly found in the distal piece of the PRF and membrane which incorporate more neutrophils. This kind of concentrate can possibly improve angiogenesis by communicating the enzymatic lattice metalloproteinase-9. In this manner, the incorporation of neutrophils in the PRF could be considered if angiogenesis is of interest. Investigation of the examination by Ghanaati et al. (2014) additionally uncoated that the platelets were the only ones present in every coagulum zone up to 87±13% in the L-PRF group and up to 84±16% in the A-PRF group (Figure 4). Moreover, the outcomes indicated that T lymphocytes (L-PRF: 12±5%, A-PRF:17±9%), B lymphocytes (L-PRF: 14±7%, A-PRF:12±9%), CD34 positive stem cells (L-PRF: 17±6%, A-PRF:21±11%), and Monocytes (L-PRF: 19±9%, A-PRF:22±8%) not over 30% of the total length of the clot have been found past a specific point since they are conveyed close to the BC produced by the centrifugation procedure.



Fig. 4. *Advanced-PRF (A-PRF) compared with L-PRF total scan of a fibrin clot along its longitudinal axis (Masson-Goldner staining). RBC represents the fraction of red blood cells. The buffy coat (BC) is the transformation zone between the RBC fraction and the fibrin clot and FC represents the fibrin clot. The three bars inside the scan and the arrows show the close-ups of the respective areas. The red arrows mark the cells that are trapped within the fibrin network. On the right, the content of various types of cells in the two types of platelet-rich fibrin. Right: head and body micrographs of equine PRF membrane containing CD34+ stem cells [21].*



Fig. 5. *MSC and HUVEC migration is shown in response to factors released by L-PRF, L-PRP and blood clots (BC). Migration of MSC and HUVEC was assessed in Boyden chambers with media collected after 8 hours and 1, 3, 7, 14 and 28 days of L-PRP, L-PRF and blood clots compared to media containing 10% FBS and change expressed in turn. Data are presented as mean ± SD from a triple of 11 samples. The statistical evaluation was carried out using the repeated two-way ANOVA and the Bonferroni post hoc test. Significant differences are indicated for the migration of CSM and HUVEC between platelet concentrates at different times: * p <0.05, ** p <0.01, *** p <0.001. (from Schär et al. 2015 modified) [21].*

II. Materials and Methods

II.1. L-PRF processing

L-PRF® generation protocol: blood is promptly centrifuged within 2 minutes from withdrawal, following the consequent steps: 30" of increasing speed, 12' at 2700 rpm (816 g-force) and 36" of deceleration and capture. The outcome product is made of three membranes: PPP (Platelet-poor plasma at the top), PRF (central clot), Red Blood Cells (RBCs) at the base, with Duo centrifuge (Process for PRF, France) (Figg.1 and 4). Resulting PRF clots are assembled and red blood cells are expelled with the aid of scissors, without macroscopical damage at PRF structure expense.

a prospective investigation of equine blood was performed, which has been collected in test tubes without anticoagulant plastic-coated glass, nor a gel separator (Vacutainer tubes for serum 9.0 ml), for the generation of L-PRF clots and membranes by six healthy horses of different ages (average ± SD, 10 ± 4.1 years, ranging from 4 to 17 yrs), gender, and breed.

A written/oral consent was given by the owners of all horses and the blood collection method has been performed as per the current AVMA guidelines.

The blood was collected rapidly with 9 cc with needle 19G to Vacutainer tubes (22" average value, of under 25" per tube) and quickly (within 1 min) centrifuged by the previous depiction to a temperature greater than 21°C. Glass tubes coated with plastic without anticoagulant or gel separator (A-PRF+ Vacutainer

tubes for Serum 9.0 ml) were utilized to deliver additionally A-PRF clots and membranes at an encompassing temperature above 21°C (21-30°C).
Fibrinogen is at first concentrated in the center and a predominant portion of the test tube, which is in between red blood cells (RBCs) at the base and the Platelet-Poor Plasma (PPP) at the top. Clot compression by means of a compression framework (L-PRF box) fundamentally stimulates cell proliferation and neovascularization [10].
Furthermore, with the standard formulations, PRFs can be acquired in injectable form (I-PRF). I-PRF is obtained by creating a PRF, which isn't in this manner compressed. Profitably, this injectable material can coagulate following injection (within 10-12 minutes) to form a biomaterial and can be combined with any biomaterial of choice for non-covalent consolidation [11].
The PRF was subdivided into 3 regions, of equivalent length (Figg.3,4) and platelet presence in every area was observed through S.E.M., through Optic Microscope in horse-derived preparations[12].
Region 1 is the region nearest to the red clot and shows a prominent number of platelets totals, showing a few lymphocytes and other white blood cells. Platelet count is decreased as the distance from the red clot is expanded. Within region 2 (central region), we observed fibrin fibers (primary and secondary fibers) and a few platelets. Within region 3, the fibrin mesh is very clear, while the platelet count is low (Fig.3).
Under a clinical perspective, L-PRF and derivatives (A-PRF, i-PRF) shows great dealing with properties: single L-PRF clots can be transformed into membranes of fitting thickness and measurements, on account of the "L-PRF Wound Box"; combining at least two membranes is valuable (can likewise be sutured) to make a bioactive membrane of greater measurements, to cover and form greater grafts. L-PRF membrane can likewise be cut and custom-fitted. Being adaptable enough, it adjusts to various anatomical regions.
L-PRF/i-PRF family adjusts to the necessities of the different surgical mediation. Much the same as clots and membranes, L-PRF has shape and volume effectively combined with the incredible greater part of surgical procedures, as filling strategy and healing biomaterial apposition, or as protecting membranes for wound healing. Moreover, it is easy to prepare, additionally in extraordinary amounts, and cost-effective, making it especially suitable for ordinary clinical practice. It was effectively utilized by AA, particularly in the treatment of cutaneous diabetic ulcers, additionally with osteomyelitis presence [13].

II.2. Macroscopic Analysis

After centrifugation, the L-PRF and A-PRF clots (Fig.4) product expelled from the test tube utilizing sterile tweezers and a smooth spatula to delicately discharge the red clot from the buffy coat. Every L-PRF/A-PRF clot acquired was put in a tray for estimating the weight and size with a computerized scale from a goldsmith and a digital device.

The compression of the clot was done with the L-PRF Wound Box we designed with a compression of 142.437 Pa/cm^2 constant for two, five, ten, fifteen minutes (no longer lasting compressions were tested on the grounds that they did not demonstrate to be useful in the past examination contrasted with the two-minute investigation). This strategy enabled us to obtain, from each clot, the L-PRF membranes, which were independently gauged and estimated with a computerized device.
At long last, they were captured with a computerized camera (Nikon) to have the option to ascertain the surface in cm^2 as per the strategy we reported in the literature [14]. The surface region in cm^2 of clots and the membranes were estimated with the Calcderm estimation software [14].

II.3. Optical Microscopy Procedure

The membranes were fixed in 10% neutral buffered formalin for 24 h at ambient temperature for incorporation in paraffin. Consequent segments of 4 □m were performed along the midpoint of the membranes and were stained with Haematoxylin-Eosin. Each segment was isolated into three equivalent estimated areas: proximal (head), center (body), and distal (tail). Every zone of these segments was seen through an optical microscope (Kern OBN-148) and examined by checking the noticeable cell bodies (marked in dark purple, for the most part leukocytes) at the central point of each observed zone with a magnification of 25×, 40×, 60×, and 100× (immersion). The complete number of counted cell bodies was utilized to correlate their appropriation between the three membrane regions (head, body, and tail). A large portion of the cells was concentrated in the proximal region (head), nearest to the red clot.

Smears of blood prepared by residual blood in the tubes were analyzed for a morpho-scientific appraisal after expulsion of the PRF clot with a spatula (two for each tube), separating the clot at 0 min by centrifugation and fixing them with alcohol 90% for a Grŭnwald-May-Giemsa coloring stain so as to recognize the different corpuscular components, specifically platelets and neutrophils, to contrast them in connection with the assessment blood count.
A blood test was additionally taken from each horse to achieve a blood count utilizing K3E 5.4 mg EDTA tubes (VacuMed).
The supernatant got from compression with the Wound Box membranes L-PRF and A-PRF was separated between the 0 min and has been safeguarded in a test tube with K3E 5.4 mg EDTA for blood count examination. It was contrasted and the basal one and with the corpuscular components of the counts performed on smears got from the red clot as an indirect estimation of the platelet and the leukocyte concentrations of the L-PRF.

The supernatant got from the squeezing of L-PRF/A-PRF at 0 min was analyzed with a blood count in standard lodging. Since the direct estimation of platelet concentration of the PRF is not yet conceivable, we determined the residual platelet concentration with the subtraction strategy as per the accompanying formula from Watanabe e al. 2017 [15]:

PLT/WBC in A-PRF and L-PRF =PLT/WBC in the whole blood-[(PLT/WBC in red clot)-(PLT/WBC in the serum over the clot of PRF)-(PLT/WBC in the supernatant after compression of the clot PRF)]

The examinations were performed with a Cell Dyn 3500 R cell counter (ABBOTT).

II.4. Statistical Analysis

The statistical significance for the contrasts between the two groups was determined utilizing Student mins t-test for rehashed measures for parametric factors and with the χ^2 for non-parametric factors. P values < 0.005 were considered statistically significant. All data were analyzed utilizing the Discipline Biomedical Statistics of Stanton-Glantz 2007 software package, version 6.0.

III. Results

The methodology was well-tolerated in all animals. No significant contrasts were found in the primary hemato-scientific comparison, which had an average concentration of RBC 9.8×10^6/mL (range:7-13), WBC 5.1×10^3/mL (range:5-13) (±0.37 C.I. 95%) (p=0.24) and a platelet count average of 106.8×10^3/mL (run: 100-350) (±15.3 I.C.95%) (p=0.5). It was impractical to directly evaluate the platelet concentration and WBC trapped within the L-PRF clot, which was derived in an indirectly by contrasting the mean estimations of entire blood, the mean estimations of the supernatant acquired after compression of the clot at 2 min, and the average values got with the counts of smears of the red clot after the evacuation of the L-PRF clot. Table 1 shows the number of leukocytes, red blood cells and platelets in the entire blood (control group) and red blood clot after collection of the PRF membrane (test group) liable for remedial potentiation. Table 2 relates the features of clots and membranes of PRF acquired in humans (centrifugal Intraspin) reported by Pinto et al. [16] and those we observed in the horse model (centrifuge DUO). In this examination, it was checked that there are significant contrasts in the attributes of the clot (weight), yet these distinctions are eliminated when the membranes got from the compression were inspected. This perception, as we would like to think, would be assigned to various content of exudate (weight of the exudate is 1.47±0.13 g in humans, 3.05±0.11 g in horses, p = 0.000).

TABLE 1. *Leukocytes, RBC and Platelets number in whole blood (control group) and red clot after PRF membrane collecting (test group)*

	Leukocytes/µl		RBC/µl		Platelets/µl	
	Mean	Range	Mean	Range	Mean	Range
Control	6.900	6.100-7.800	5.19 (10^6)	5.01-5.52 (10^6)	2.66 (10^5)	2.18-3.09 (10^5)
Group 1	3.500	3.000-3.800	5.89 (10^6)	5.75-6.08 (10^6)	6.000	4.000-8000
Group 2	3.600	3.300-4.000	5.84 (10^6)	5.78-5.91 (10^6)	7.000	6.000-9000

TABLE 2. *Comparison of membranes obtained from human blood (Pinto et al., 2014) and from equine blood.*

	Man (n = 8)	Horse (n = 6)		
Variable	Average (±SD)		Student mins *t*	Significance
Final T° test tube (°C)	27.5 (±0.66)			
Weight of the Clot (g)*	2.09 (±0.19)	4.23 (±0.55)	$p = 0.000 < 0.005$	S
Weight of the Membrane (g)	0.62 (±0.15)	0.78 (±0.08)	$p = 0.036 > 0.005$	NS
Exudate Weight (g)	1.47 (±0.13)	3.05(±0.11)	$p = 0.000 < 0.005$	S
Length of the Clot (mm)	35.69 (±3.43)	44.38(±3.83)	$p = 0.000 < 0.005$	S
Width of the Clot (mm)	12.81 (±0.75)	14.74(±1.23)	$p = 0.003 < 0.005$	S
Height of the Clot (mm)		7.02 (±1.09)		
Surface Area of the Clot (mm²)		4.10 (±0.86)		
Length of the Membrane (mm)	34.81 (±2.95)	36.81(±3.18)⇮	$p = 0.248 > 0.005$	NS
Width of the Membrane (mm)	12.25 (±0.71)	13.02(±1.01)⇮	$p = 0.119 > 0.005$	NS
Height of the Membrane (mm)		3.02 (±0.51)⇮		
Surface Area of the Membrane (cm²)		3.08 (±0.5)⇮		
Weight ratio Clot/Blood Sample (%) 10ml	20.94 (±2.4)	32.53(±0.54)	$p = 0.000 < 0.005$	S

* The difference of the weight clot is due to a difference of exudate content; ⇮ Average values (±D.S.) after 2 min compression at 30 °C;
N.B.: the values are not in relation to the content of Hb and erythrocytes in whole blood.

In the present sudy, the size of the membranes is not seen as in connection to the hemoglobin content or the content of erythrocytes encountered in the blood count baseline. In optical microscopy (Figure 3), the vast majority of the cell bodies (stained in dark purple for the nuclei) were concentrated in the proximal part (head) of every membrane, the last 1/4 was seen at the center, and the distal part had just residual traces of cell bodies. Optical microscopy has not, be that as it may, permitted the perception of the definite condition of these cell bodies in more prominent formulation.

The outcomes of the blood counts of entire blood and of the supernatant acquired from the clot after 0 min compression are contrasted and the counts of erythrocytes, platelets, and the WBC smear of the red clot after 0 min are shown with the comparing statistical tests in Table 3.

TABLE 3. *Outcomes of the blood counts of entire blood, of the supernatant acquired by compression of the clot at 0 min contrasted and the counts of erythrocytes, platelets, and WBC of the red clot smear at 0 min, with a trial of significance. * preparing performed on two correlations. The theoretical content of RBC, WBC, and PLT in the L-PRF membranes at 0 min with significance tests. p > 0.05 = +0.5% non-significant distinction; p < 0.01 = – 1% significant contrast.*

Type	CBC blood	CBC supernatant at 0 min	Smear C.R. 0 min	Between CBC blood and supernatant 0 min			
	Average ± D.S.	Average ± D.S.	Average ± D.S.	*t-test**		χ^2	
RBC	7,648,000 ± 11,309.81	13,428 ± 21345	7,399,440 ± 27,039.76	$p = 0.411 > 0.05$	NS	$p = 0.000 < 0.005$	S
WBC	5150 ± 369	30 ± 27.99	8.5 ± 2.12	$p = 0.255 > 0.05$	NS	$p = 0.000 < 0.005$	S
PLT	106,780 ± 153.51	479 ± 77.614	500 ± 707.11	$p = 0.031 < 0.05$	S	$p = 0.000 < 0.005$	S
Neutrophil	3046 ± 857	0.29 ± 0.76		$p = 0.280 > 0.05$	NS	$p = 0.991 > 0.005$	NS
Basophils	4.2 ± 1.3	2.29 ± 2.14		$p = 0.785 > 0.05$	NS	$p = 0.611 > 0.005$	NS
Lymphocites	1606 ± 668	19 ± 23.15		$p = 0.238 > 0.05$	NS	$p = 0.000 < 0.005$	S
Monocytes	490.2 ± 138.06	4.57 ± 7.68		$p = 0.631 > 0.05$	NS	$p = 0.928 > 0.005$	NS
Eosinophils	5.4 ± 5.37	4 ± 9.71		$p = 0.906 > 0.05$	NS	$p = 0.316 > 0.005$	NS

Type	Membrane L-PRF/A-PRF 0 min	
	No./µl	%
RBC	21.6012	0.0028%
WBC	5111.15	99.24%
PLT	105.801	99.00%

Table 3 exhibits the measurably noteworthy distinction between the content of RBC, WBC, and platelets between the supernatant got from the compression of the clot at 0' and the values acquired with the blood count. There is likewise statistically significant contrast shown between the content of RBC, WBC, and PLT in smears got from the red clot at 0 min, as shown in Figures 3 A–C at different magnifications. Table 3 likewise shows the Theoretical content of RBC, WBC, and PLT in L-PRF/A-PRF membranes got from the distinction of these corpuscular components between entire blood, the supernatant at 0 min, and the smear of the red clot at 0 min. The Student t-test shows noteworthy contrasts between RBCs at 0 min and PLT at 0 min in L-PRF/A-PRF membranes and the blood count test.

The content of RBC in the membranes is 0.0028%, that of WBC is 99.24%, and that of PLT is 99.0%, contrasted with the content in entire blood.

The examination performed by McLellan et al. [17] has demonstrated that the equine PRF is like that of humans, giving a quick and constant source of tissue growth factors. Our examination has endeavored to standardize the preparation of the L-PRF/A-PRF system which, while the residual procedure of simple execution and minimal effort does not require specialized hardware, yet has a specific steadiness in the generation of membrane as far as L-PRF/A-PRF macroscopic and microscopic characteristics. The autologous platelet concentrates are promising in the field of regenerative medicine because of the abundance of growth factors.

The L-PRF represents a critical advancement in the evolution of platelet concentrates since it is basically a fibrin membrane with platelets and leukocytes trapped within alongside stem cells. These solid membranes have great dealing with features and can be immovably sutured in an anatomically-desired area during open surgeries. Nonetheless, the physical and organic properties are moderately obscure and presently yet to be completely studied.

The L-PRF/A-PRF will frame when the steps portrayed above are stringently observed.

One of the significant contemplations in creating a decent membrane is the postponement in the time between blood collection and centrifugation, just like the processing temperature. The accomplishment of the procedure depends totally on the speed of collection of blood and the prompt exchange into a centrifuge, as a rule within one minute, and by a centrifugation temperature and higher squeeze at 21°C (between 21 and 30°C).

You cannot create a clot of well-structured L-PRF/A-PRF (with its particular cell content, design of the matrix, and profile of the release of growth factors) if the collection of blood is delayed and not homogeneous, or if the centrifugation temperature is underneath 21°C or more than 30°C; rather, it will form a conflicting, brittle mass of fibrin with obscure content.

The L-PRF/A-PRF capacities as a temporary extracellular network, which is changed into useful tissue during healing, and can be exposed to mechanical forces and healing results with progress, which relies upon the structural integrity and, therefore, it is important to explain its physical properties. The L-PRF/A-PRFs look like dense connective tissue with predominant handling features. Thusly it is expected that, as in the L-PRF, additionally in the A-PRF there is a low rigidity.

With an elastic modulus of 0.470 MPa (SD±0.107) the L-PRF membrane stretches to twice its underlying length before breakage (of 215% strain). This information affirms the published literature [18] which reported a low rigidity (1–10 MPa) and a high voltage (up to 150%) before breaking down.

Based on these outcomes, plainly L-PRF/A-PRF is another biomaterial with one of a kind highlight: the foreseen preparation of autologous blood, the straightforwardness of the protocol, the characterized architecture, the noteworthy mechanical properties, and the abundance of derived growth factors from stimulated platelets. Our trials on equine blood will no doubt have the option to improve our comprehension of healing, as well as add to advancing the field of personalized medicine.

Limitations that were found in the clinical setting and utilization of these products include:

1) Since PRF is an autologous product, an expanded prerequisite for the biomaterial accessibility is troublesomely accomplished. Subsequently, its utilization in surgeries must be firmly controlled.

2) PRF contains circling immune cells, just as antigenic molecules that avoid its application as allogenic material; an expanded hazard for the transmission of infectious ailments is likewise to be considered.

Now, among the various parameters that were excluded from this sort of classification, we perceived: platelet concentration, leukocyte concentration and the corresponding measure of the distinctive leukocyte types. Platelet concentration-related issues are non-existent, as all platelets included in the blood

test are activated and coordinated within the clot's fibrin framework.

Concerning the leukocytes' count and concentration, their impact ought to be studied with specific care, as their presence or absence could clarify the clashing outcomes we observed.

An ongoing report by Kitamura Y. et al.[19] (2018) shows a technique for direct estimation of platelet count in PRF. These authors utilized a monetarily accessible recombinant t-PA, Alteplase (GRTPA®; Mitsubishi Tanabe Pdamagea Corp., Osaka, Japan) through an absorption strategy. Here, they have demonstrated that t-PA is ground-breaking enough to have the option to count scattered platelets accumulated into platelet-improved insoluble fibrin frameworks.

IV. CONCLUSIONS

In conclusion, we can assert that to accomplish a standard methodology for PRF preparation as graft material for tissue restoration purposes, we propose the work of PRF membrane's area with the most elevated conceivable platelet enhancement and, in addition, we recommend avoiding squeezing the entirety of the PRF clot plasma. Consequently, it is fitting to compress the clot with a compression gadget (L-PRF Wound Box). It's difficult, consequently, to control absolutely the human-derived materials' quality, as PRF preparations, however it is imperative to apply the most noteworthy conceivable quality-control check on PRF preparations before their clinical application.

Presently, their conveyance depends on ineffectively controlled bulk discharges. As a result, delayed medications require numerous treatments, for example, various injections I-PRF. These outcomes in firmly fluctuating growth factor concentrations, which hinders clinical consistency. Biomaterials can go about as controlled discharge gadgets, which will consider continued or even on-demand conveyance of these growth factor cocktails. Moreover, it very well may be imagined that biomaterials can covalently bind specific growth elements to locally hold significant levels of these molecules.

Further clinical, histo-scientific and statistical examinations are required to comprehend the advantages of this new platelet concentration method. Nevertheless, we cannot clear aside the fact that, when gotten from an autologous blood test, produced PRF is rare and just a limited volume can be utilized. This is an impediment for methodical PRF application in Regenerative Surgery interventions. Regardless of whether the potential uses of PRF are sufficient, exact information on the biomaterial is primary, including data for its biology, efficiency and limits, to upgrade its application in everyday clinical practice.

Cell migration assumes a critical role in the healing procedure. MSCs represent a cell pool, able to recreate the damaged tissue, and endothelial cells' contribution to angiogenesis. Migration models instigated by the supernatant of platelet concentrates' culture does not contrast between the two kinds of cells. The solider MSCs and HUVECs migration were seen as an answer to L-PRF. The entirety of the above signifies that L-PRF could be valuable as a healing biomaterial, and as a natural anti-hemorrhagic agent to be utilized at surgical sites [20, 21].

Recently the AA have collaborated with the Japanese group of Kitamura to elaborate a statistical method (mathematical calculation), statistically valid, which can allow to predict the presence of cells in the PRF starting from the evaluation of a blood count test. Therefore, validate a simple and inexpensive system to calculate the precise number of platelets and leukocytes present in platelet concentrates [22].

V. REFERENCES

[1] E. Pretorius, S. Briedenhann, J. Marx, E. Smit, C.van der Merwe, M. Pieters and C. Franz, Ultrastructural comparison of the morphology of three different platelet and fibrin fiber preparations, The Anatomical Record, vol. 290, pp. 188-198, 2007 https://doi.org/10.1002/ar.20413.

[2] J. Choukroun, F. Adda and C. Schoeffler, Une opportunitè en paro-implantologie: le PRF, Implantodontie, pp. 55–62, 2001.

[3] A. Crisci, U. De Crescenzo and M. Crisci, Platelet-Rich Concentrates (L-PRF, PRP) in tissue regeneration: control of apoptosis and interactions with regenerative cells, J Clin Mol Med, vol.1, pp. 5-12, 2018 https://doi.org/10.15761/JCMM.1000116.

[4] R.I. Litvinov and J.W. Weisel, What Is the Bioscientific and Clinical Relevance of Fibrin?, Semin. Thromb. Hemost. vol. 42, pp. 333–343, 2016 https://doi.org/10.1055/s-0036-1571342.

[5] D.A. Soloviev, S.L. Hazen, D. Szpak, K.M. Bledzka, C.M. Ballantyne, E.F. Plow and E. Pluskota, Dual Role of the Leukocyte Integrin M 2 in Angiogenesis, J. Immunol. vol. 193, pp. 4712–4721, 2014, https://doi.org/10.4049/jimmunol.1400202.

[6] A. Crisci, D. Lombardi, E. Serra, G. Lombardi, F. Cardillo and M. Crisci, Standardized protocol proposed for clinical use of L-PRF and the use of L-PRF Wound Box®, J Unexplored Med Data, vol.2, pp. 77-87, 2017, https://doi.org/10.20517/2572-8180.2017.17.

[7] S. Ghanaati, P. Booms, A. Orlowska, A. Kubesch, J. Lorenz, J. Rutkowski, C. Landes, R. Sader, C. Kirkpatrick and J. Choukroun, Advanced Platelet-Rich Fibrin: a new concept for cell- based tissue engineering by aims of inflammatory cells, J Oral Implantol, vol.40, pp.679-689, 2014 https://doi.org/10.1563/aaid-joi-D-14-00138.

[8] J.Choukroun, Advanced-PRF and i-PRF: platelet concentrates or blood concentrates?, J Phaseont Med Clin Pract, vol.1, pp.1-3, 2014

[9] R.J.Miron, M. Fujioka-Kobayashi, M. Hernandez, U. Kandalam, Y. Zhang, S. Ghanaati and J. Choukroun, Injectable platelet rich fibrin (i-PRF): opportunities in regenerative dentistry?, Clin Oral Invest, vol.21, pp.2619-2627, 2017 https://doi.org/10.1007/s00784-017-2063-9.

[10] M. Kobayashi, T. Kawase, M. Horimizu, K. Okuda, L.F. Wolff and H. Yoshie, A proposed protocol for the standardized preparation of PRF membranes for clinical use, Bioscientifics, vol.40, pp.323-329,2012, https://doi.org/10.1016/j.bioscientifics.2012.07.004.

[11] E.D.M. Dohan, T. Bielecki, R. Jimbo, G. Barbé, M. Del Corso, F. Inchingolo and G. Sammartino, Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF), Current Phamaceutical Biotechnology, vol.13,pp.1145-1152,2012 https://doi.org/10.2174/138920112800624382.

[12] A. Crisci, G. Benincasa, M. Crisci and F. Crisci, Leukocyte Platelet-Rich Fibrin (L-PRF), a new biomembrane useful in tissue repair: basic science and literature review, Biointerface Res Appl Chem, vol.8, pp.3635-3643, 2018

[13] A. Crisci, G. Marotta, A. Licito, E. Serra, G. Benincasa and M. Crisci, Use of leukocyte platelet (L-PRF) rich fibrin in diabetic foot ulcer with osteomyelitis (three clinical cases report), Diseases, vol.6, pp.30, 2018 https://doi.org/10.3390/diseases6020030.

[14] A. Crisci, M. Crisci and E. Boccalone, Final results of an experimental research about a technique of measurement of skin lesions. Esperienze Dermatologiche, 2014, vol.16, pp.147-152, 2014

[15] T. Watanabe, K. Isobe, T. Suzuki, H. Kawabata, M. Nakamura, T. Tsukioka, T. Okudera, H. Okudera, K. Uematsu, K. Okuda, K. Nakata and T. Kawase, An Evaluation of the Accuracy of the Subtraction Method Used for Determining Platelet Counts in Advanced Platelet-Rich Fibrin and Concentrated Growth Factor Preparations, Dent J, , vol.5, pp.7, 2017 https://doi.org/10.3390/dj5010007.

[16] N.R.Pinto, A. Pereda, P. Jimenez, M. Del Corso, B.S. Kang, H.L. Wang, M. Quirynen and E.D. Dohan, The impact of the centrifuge characteristics and centrifugation protocols on the cells, growth factors and fibrin architecture of a leukocyte-and platelet-rich fibrin (L-PRF) clot and membrane. Part 2: macroscopic, photonic microscopy and Scanning Electron Microscopy analysis of 4 kinds of L-PRF clots and memebranes, POSEIDO Journal, , vol.2, pp.141-154,2014 https://doi.org/10.1080/09537104.2017.1293812.

[17] J. McLellan and S. Plevin, Temporal release of growth factors from platelet-rich fibrin (PRF) and platelet-rich Plasma (PRP) in the horse: a comparative in vitro analysis, Intern J Appl Res Vet Med, vol.1, pp.48-57, 2014

[18] F.K.Hasan, Characterization of leukocyte-platelet rich Fibrin, a novel biomaterial, 2015 http://scholarscompass.vcu.edu/etd

[19] Y. Kitamura, T. Watanabe, M. Nakamura, K. Isobe, H. Kawabata, K. Uematsu, K. Okuda, K. Nakata, T. Tanaka and T. Kawase, Platelet Counts in Insoluble Platelet-Rich Fibrin Clots: A Direct Method for Accurate Determination, Front Bioeng Biotechnol, vol.6, pp.4, 2018 https://doi.org/10.3389/fbioe.2018.00004.

[20] A. Crisci, S. Manfredi and M. Crisci, Fibrin Rich in Leukocyte-Platelets (L-PRF) and Injectable Fibrin Rich Platelets (I-PRF), Two Opportunity in Regenerative Surgery: Review of The Sciences and Literature, IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), vol.18, pp.66-79, 2019 https://doi.org/10.9790/0853-1804106679.

[21] A. Crisci, M.C. Barillaro, G. Lepore and F. Cardillo, F., L-PRF Membrane (Fibrin Rich in Platelets and Leukocytes) and Its Derivatives (A-PRF, i-PRF) are Helpful as a Basis of Stem Cells in Regenerative Injury Treatment: Trial Work on the Hors, International Blood Research & Reviews, vol.10(2), pp.1-14, 2020 https://doi.org/10.9734/ibrr/2019/v10i230117.

[22] A. Crisci, T. Kawase, R. D'Adamo and M. Crisci M, Experimental research on a technique for quantification of platelets and leukocytes in secondgeneration platelet concentrates, International Journal of Current Medical and Pharmaceutical Research, vol.05(12), pp.4792-4799, 2019 http://dx.doi.org/10.24327/23956429.ijcmpr201912804